Management of Patients With Ventricular Arrythmias and the Prevention of Sudden Cardiac Death

American College of Cardiology, American Heart Association, Heart Rhythm SocietyPublished: December 19, 2018

Pages:29
Format:Spiral Bound
Dimensions:4.25" x 7.25"

$17.95

A PDF version of this Pocket Guide is also available!

$17.95

Graded recommendations for:
- Syncope
- 12-lead ECG and Exercise Testing
- Ambulatory Electrocardiography
- Implanted Cardiac Monitors
- Noninvasive Cardiac Imaging
- Assessment
- Genetic Counselling
- Invasive Imaging: Cardiac Catheterization
- Electrophysiological Study
- Pharmacological Prevention of SCD
- Surgery and Revascularization Procedures in Patients With Ischemic Heart Disease
- Surgery for Arrhythmia Management
- Autonomic Modulation
- Management of Cardiac Arrest
- Secondary Prevention of SCD in Patients with Ischemic Heart Disease
- Coronary Artery Spasm
- Primary Prevention of SCD in Patients with Ischemic Heart Disease
- Recurrent VA in Patients With Ischemic Heart Disease
- Nonischemic Cardiomyopathy (NICM)
- Secondary Prevention of SCD in Patients With NICM
- Primary Prevention of SCD in Patients With NICM
- Treatment of Recurrent VA in Patients With NICM
- Arrhythmogenic Right Ventricular Cardiomyopathy
- Hypertrophic Cardiomyopathy (HCM)
- Myocarditis
- Cardiac Sarcoidosis
- HFr EF
- LVAD
- ICD Use After Heart Transplantation
- Neuromuscular Disorders
- Cardiac Channelopathies
- Congenital Long QT Syndrome
- Catecholaminergic Polymorphic Ventricular Tachycardia
- Brugada Syndrome
- Early Repolarization “J-wave” Syndrome
- Short QT Syndrome
- VA in the Structurally Normal Heart
- Outflow Tract VA
- Papillary Muscle VA (PVCs and VT)
- Interfascicular Reentrant VT (Belhassen Tachycardia)
- Idiopathic Polymorphic VT/VF
- PVC-Induced Cardiomyopathy
- Pregnancy
- Older Patients With Comorbidities
- Medication-Induced Arrhythmias
- Adult Congenital Heart Disease
- Subcutaneous Implantable Cardioverter-Defibrillator
- Wearable Cardioverter-Defibrillator
- Catheter Ablation
- Postmortem Evaluation of SCD
- Terminal Care
- Shared Decision-Making
Tables
- Table of Definitions of Commonly Used Terms in this Document
- Important Considerations in the Evaluation of Patients With Known or Suspected VA
- Pharmacological Characteristics of Available Antiarrhythmic Medications for Treating VA
- Major Clinical Features Associated With Increased Risk of SCD in Patients With HCM
- Neuromuscular Disorders Associated With Heart Disease
- Commonly Used QT-Prolonging Medications
- Congenital Heart Disease: Risk Factors for VA/SCD
Figures
- SCD Incidence and Total Events
- SCD and Clinical Subsets
- Long-QT Syndrome Type 1 (ECG)
- Long-QT Syndrome Type 2 (ECG)
- Long-QT Syndrome Type 3 (ECG)
- Exercise-Induced Polymorphic VT in Catecholaminergic Polymorphic Ventricular Tachycardia (ECG)
- Brugada Syndrome (ECG)
- Incremental Cost-Effectiveness of ICD by Years of Life Added (Example)
Algorithms
- Management of Sustained Monomorphic VT
- Secondary Prevention in Patients With Ischemic Heart Disease
- Primary Prevention of SCD in Patients With Ischemic Heart Disease
- Treatment of Recurrent VA in Patients With Ischemic Heart Disease or NICM
- Secondary and Primary Prevention of SCD in Patients With NICM
- Prevention of SCD in Patients With HCM
- Prevention of SCD in Patients With Cardiac Sarcoidosis
- Prevention of SCD in Patients With Long QT Syndrome
- Prevention of SCD in Patients With Brugada Syndrome
- Prevention of SCD in Patients With Long QT Syndrome
- Prevention of SCD in Patients With Adult Congenital Heart Disease